Blocking IL-13 to see how it changes itch and skin pain sensitivity
Official title: The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers
Run by Aalborg University · NCT06503510 · Data updated 2026-11-12
This trial will test whether lebrikizumab, a drug that blocks IL-13, changes itch and skin pain sensitivity in healthy adults and people with atopic dermatitis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Aalborg University Academic / other |
| Drugs / interventions | Lebrikizumab |
| Locations | 3 sites (Gistrup, Aalborg and 2 other locations) |
| Status | Recruiting |
| Started | January 6, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT06503510 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–60 who can attend in-person visits and are either healthy or have atopic dermatitis and meet the study's exclusion criteria may be eligible.
✕Probably not a fit
People who are pregnant or breastfeeding, use interfering medications, have active skin lesions or tattoos in the test area, have substance use or certain neurological, dermatological, immunological, cardiac, or psychiatric conditions, or cannot attend in-person visits are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial gives the IL-13 blocking antibody lebrikizumab and uses standard itch/pain provocation agents (histamine, cowhage, BAM8-22) to measure sensory responses. Both healthy adults and people with atopic dermatitis are included so researchers can compare responses across groups. Outcomes include subjective itch and pain ratings and objective sensory testing to map IL-13's role in neuronal sensitivity. This is the first human use of lebrikizumab specifically as an experimental tool to modulate IL-13 for mechanistic study of itch and pain.
Why it matters
Potential benefit: If successful, this work could clarify how IL-13 drives itch and pain and help guide better treatments that reduce these symptoms in people with atopic dermatitis.
How similar studies have gone: Drugs that block IL-13, including lebrikizumab, have reduced inflammation and itch in prior atopic dermatitis trials, but using such antibodies as experimental tools to probe acute itch and pain sensitivity in humans is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy men and women * 18-60 years Exclusion Criteria: * Pregnancy or lactation * Drug addiction defined as any use of cannabis, opioids, or other drugs * Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.) * Moles, wounds, scars, or tattoos in the area to be treated or tested * Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment). * Use of systemic and topical corticosteroids * Consumption of alcohol or painkillers 24 hours before the study days and between these * Acute or chronic pain * Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials) * Lack of ability to cooperate
Where it's running
-
Aalborg University
Gistrup, Aalborg, Denmark Recruiting -
Cnap
Gistrup, Aalborg, Denmark Active not recruiting -
Aalborg University
Aalborg, Denmark, Denmark Not yet recruiting
Study contacts
- Study coordinator: Silvia Lo Vecchio
- Email: slv@hst.aau.dk
- Phone: 21397785
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Topical Roflumilast Cream for Itch in Atopic Dermatitis: See If It Helps Over 4 Weeks
This trial tests whether a 0.15% topical roflumilast cream can reduce itching in people 12 years and older with mild to moderate atopic dermatitis over 4 weeks.
-
Exploring How Contagious Itch Works on the Skin
This study tests how itch spreads when histamine, cowhage, or a placebo are applied to the forearms to see how people feel itch and pain.
-
Placebo effects on histamine and cowhage-induced itch
This one-time, 1½-hour session will test whether applying a harmless cream reduces histamine- and cowhage-induced itch in healthy adults aged 18–60.
-
Mapping itch and pain receptor locations on the face
We will test how itch and pain are felt at different spots on the face in healthy adults by applying mild provocations (histamine, cowhage, capsaicin) and measuring responses over three days.
-
Using Virtual Reality and Hypnosis to Reduce Chronic Itch
This study is testing whether using virtual reality combined with hypnosis can help people with chronic itch feel better.
-
Effects of motor imagery on pain and itch perception
This study tests if imagining movements can help reduce pain and itch sensations in people experiencing these feelings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.